Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CXFTH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Serclutamab talirine
|
|||||
| Synonyms |
ABBV-321; ABBV321; ABBV 321
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Serclutamab
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB, S238C).
|
|||||
| Combination Type |
Talirine
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Partial Response (PR) | 4.17% | High EGFR expression (EGFR+++) | ||
| Patients Enrolled |
Advanced, histologically confirmed solid tumors associated with EGFR overexpression (centralized testing).
|
||||
| Administration Dosage |
Ser-T intravenously once every 4 weeks (Q4W; 5-50 ug/kg) in the dose-escalation phase.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | ||||
| Primary Endpoint |
One patient was PR (N=1/24, 4.17%), 6 patients was SD (N=6/24,25.00%). Median DOR (CR + PR + SD)=6.40 months (95% CI 3.0not reached). The median PFS=1.8 months (95% CI 1.3-5.8), median OS=7.10 months (95% CI: 4.1-12.3).
|
||||
| Other Endpoint |
Ser-T RP2D regimen=25 ug/kg Q4W.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Partial Response (PR) | 4.20% | High EGFR expression (EGFR+++) | ||
| Patients Enrolled |
Advanced, histologically confirmed solid tumors associated with EGFR overexpression (centralized testing).
|
||||
| Administration Dosage |
Ser-T intravenously once every 4 weeks (Q4W; 5-50 ug/kg) in the dose-escalation phase.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | ||||
| Primary Endpoint |
Responses included 1 partial response (PR), 6 stable disease (SD), 14 progressive disease (PD); 3 patients were not evaluable for response. Median duration of clinical benefit (complete response + PR + SD) was 6.40 months (95% CI: 3.00-not reached).
|
||||
| Other Endpoint |
The median PFS was 1.80 months (95% CI: 1.30-5.80) and the median OS was 7.10 months (95% CI: 4.10-12.30).
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | ||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 34.00% (Day 66) | High EGFR expression (EGFR+++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO199) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 40.00% (Day 66) | Low EGFR expression (EGFR+) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO199) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 76.00% (Day 24) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,demonstrated with ABBV-321 dosed at 0.15 mg/kg 2 every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing malignant mesothelioma PDX model (PDX: 1174) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.57% (Day 68) | Moderate EGFR expression (EGFR++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO207) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.20% (Day 70) | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO199) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 91.60% (Day 66) | Moderate EGFR expression (EGFR++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO207) | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.70% (Day 74) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO207) | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.80% (Day 33) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression, administered at 0.5 mg/kg on a Q7D 6 regimen.
|
||||
| In Vivo Model | EGFR-expressing colorectal adenocarcinoma PDX model (PDX: LoVo) | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.40% (Day 74) | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO207) | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.20% (Day 70) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO199) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 52.40% (Day 28) | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.0125 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 55.30% (Day 35) | Low EGFR expression (EGFR+) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of lung squamous cell carcinoma cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 70.60% (Day 28) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.025 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 73.80% (Day 38) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing A-253 CDX model | ||||
| In Vitro Model | Submandibular gland squamous cell carcinoma | A-253 cells | CVCL_1060 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.10% (Day 38) | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.3 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing A-253 CDX model | ||||
| In Vitro Model | Submandibular gland squamous cell carcinoma | A-253 cells | CVCL_1060 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.80% (Day 28) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.05 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.80% (Day 28) | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.10% (Day 31) | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing FaDu CDX model | ||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.90% (Day 30) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing HCT 116 CDX model | ||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.90% (Day 30) | Low EGFR expression (EGFR+) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,administered 0.4 mg/kg,at every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing HCT 116 CDX model | ||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 91.80% (Day 31) | Negative EGFR expression (EGFR-) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.3 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing FaDu CDX model | ||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 35) | Low EGFR expression (EGFR+) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 35) | High EGFR expression (EGFR+++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 42) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 42) | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 24) | Low EGFR expression (EGFR+) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of lung squamous cell carcinoma cell with EGFR expression,a single dose of 0.3 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
15.00 pM
|
|||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.23 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | U-87 MGvIII cells | CVCL_0022 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.70 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | U-251MG cells | CVCL_0021 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.70 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | LoVo cells | CVCL_0399 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.00 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.10 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SK-CO-1 cells | CVCL_0626 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.40 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | SF268 cells | CVCL_1689 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.50 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | M059K cells | CVCL_0401 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.50 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 10 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.80 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW403 cells | CVCL_0545 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.90 nM | High EGFR expression (EGFR+++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Primitive neuroectodermal tumor | PFSK-1 cells | CVCL_1642 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.50 nM | High EGFR expression (EGFR+++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Gliosarcoma | SF539 cells | CVCL_1691 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.60 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 201 cells | CVCL_1987 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.80 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | M059J cells | CVCL_0400 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.30 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 205 cells | CVCL_0218 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.70 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | SNB-19 cells | CVCL_0535 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.30 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW620 cells | CVCL_0547 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.60 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.60 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW1116 cells | CVCL_0544 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.70 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon carcinoma | RKO cells | CVCL_0504 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.80 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Anaplastic astrocytoma | CHLA-03-AA cells | CVCL_U616 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.80 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Rectal adenocarcinoma | SW1463 cells | CVCL_1718 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.50 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | WiDr cells | CVCL_2760 | ||
| Experiment 24 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8.00 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
| Experiment 25 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8.40 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | LN-18 cells | CVCL_0392 | ||
| Experiment 26 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 9.00 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | DLD-1 cells | CVCL_0248 | ||
| Experiment 27 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 9.50 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Cecum adenocarcinoma | LS1034 cells | CVCL_1382 | ||
| Experiment 28 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.60 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | SNB-75 cells | CVCL_1706 | ||
| Experiment 29 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11.80 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | T84 cells | CVCL_0555 | ||
| Experiment 30 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 12.00 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
| Experiment 31 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 13.90 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | Caco-2 cells | CVCL_0025 | ||
| Experiment 32 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 14.50 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | T98G cells | CVCL_0556 | ||
| Experiment 33 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 16.10 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | U-138MG cells | CVCL_0020 | ||
| Experiment 34 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 17.60 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 320DM cells | CVCL_0219 | ||
| Experiment 35 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 18.00 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Anaplastic astrocytoma | DBTRG-05MG cells | CVCL_1169 | ||
| Experiment 36 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
23.20 nM
|
|||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | A-172 cells | CVCL_0131 | ||
| Experiment 37 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 24.90 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 320HSR cells | CVCL_0220 | ||
| Experiment 38 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 28.40 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | HCT 15 cells | CVCL_0292 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.